Our results demonstrate that FGF-23 does not directly affect the mineralization of the skeletal system in CKD dialysis patients. Our findings are comparable with those of Urena et al., who found no association between serum FGF-23 and BMD [9]. This evidence concerns the gene FGF23 and chronic kidney disease.